company background image
1099 logo

Sinopharm Group SHSC:1099 Stock Report

Last Price

HK$21.95

Market Cap

HK$68.5b

7D

2.1%

1Y

9.5%

Updated

26 Dec, 2024

Data

Company Financials +

Sinopharm Group Co. Ltd.

SHSC:1099 Stock Report

Market Cap: HK$68.5b

1099 Stock Overview

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. More details

1099 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance2/6
Financial Health5/6
Dividends5/6

Rewards

Trading at 61.7% below our estimate of its fair value

Earnings are forecast to grow 4.04% per year

Pays a reliable dividend of 4.18%

Trading at good value compared to peers and industry

Risk Analysis

Has a high level of debt


My Notes

Capture your thoughts, links and company narrative

Sinopharm Group Co. Ltd. Competitors

Guangzhou Baiyunshan Pharmaceutical Holdings

SEHK:874

HK$47.0b

Shanghai Pioneer Holding

SEHK:1345

HK$2.7b

IVD Medical Holding

SEHK:1931

HK$2.6b

Tycoon Group Holdings

SEHK:3390

HK$2.8b

Price History & Performance

Summary of share price highs, lows and changes for Sinopharm Group
Historical stock prices
Current Share PriceHK$21.95
52 Week HighHK$23.65
52 Week LowHK$16.02
Beta0.85
1 Month Change7.34%
3 Month Change8.40%
1 Year Change9.48%
3 Year Change31.44%
5 Year Change-22.58%
Change since IPO-31.51%

Recent News & Updates

Recent updates

Shareholder Returns

1099HK HealthcareHK Market
7D2.1%0.6%1.9%
1Y9.5%-19.4%18.1%

Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -16.9% over the past year.

Return vs Market: 1099 underperformed the Hong Kong Market which returned 20.6% over the past year.

Price Volatility

Is 1099's price volatile compared to industry and market?
1099 volatility
1099 Average Weekly Movement5.9%
Healthcare Industry Average Movement8.3%
Market Average Movement8.6%
10% most volatile stocks in HK Market18.7%
10% least volatile stocks in HK Market4.0%

Stable Share Price: 1099 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1099's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003113,635Wanyong Lianwww.sinopharmgroup.com.cn

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.

Sinopharm Group Co. Ltd. Fundamentals Summary

How do Sinopharm Group's earnings and revenue compare to its market cap?
1099 fundamental statistics
Market capHK$68.50b
Earnings (TTM)HK$9.21b
Revenue (TTM)HK$628.29b

7.4x

P/E Ratio

0.1x

P/S Ratio

Is 1099 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1099 income statement (TTM)
RevenueCN¥590.35b
Cost of RevenueCN¥543.16b
Gross ProfitCN¥47.18b
Other ExpensesCN¥38.53b
EarningsCN¥8.65b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.77
Gross Margin7.99%
Net Profit Margin1.47%
Debt/Equity Ratio78.1%

How did 1099 perform over the long term?

See historical performance and comparison

Dividends

4.2%

Current Dividend Yield

31%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 17:02
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinopharm Group Co. Ltd. is covered by 42 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Bo LiBofA Global Research